BioWorld

Sep. 9, 2005

Replidyne Raises $62.5M; Health Care Remains Top Dog For VCs

As its first product nears the market for respiratory infections, Replidyne Inc. brought in $62.5 million in a Series D round. (BioWorld Today) Read More

Alliance Shifts Astral Subsidiary To MultiCell, Retains One-Third

Amicus Series C Garners $55M For Enzyme Efforts

Caliper Adding Size Through $22M NovaScreen Purchase

NeuroHealing Tackling Brain Injury With Dopamine Agonist

Life Science Firms Giving To Help Katrina's Victims

Other News To Note

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...